Companies › TLC Biopharmaceuticals
1 active drug program in 40 registered trials: 23 Phase 4, 11 Phase 3, 6 Phase 2; Neurology, Cardiovascular, Gastroenterology, Genitourinary.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ropivacaine (TLC590) Sodium channel alpha subunit blocker | Ion channels | Phase 3 | Postoperative Pain; Postsurgical Pain Management; End Stage Renal Disease (ESRD); Hepatic Resection … | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07259772 | Ropivacaine (TLC590) | Phase 4 | End Stage Renal Disease (ESRD) | Genitourinary | Mar 2021 |
| NCT04849455 | Ropivacaine (TLC590) | Phase 4 | Hepatic Resection | Gastroenterology | May 2023 |
| NCT05515809 | Ropivacaine (TLC590) | Phase 3 | Cardiac Surgery | Cardiovascular | Jun 2025 |
| NCT06519929 | Ropivacaine (TLC590) | Phase 4 | Rib Fractures | Other | Aug 2025 |
| NCT06784882 | Ropivacaine (TLC590) | Phase 4 | Acute Postoperative Pain | Other | Dec 2025 |
| NCT07290595 | Ropivacaine (TLC590) | Phase 2 | Post Operative Analgesia | Cardiovascular | Feb 2026 |
| NCT07290595 | Ropivacaine (TLC590) | Phase 2 | Post Operative Analgesia | Cardiovascular | Feb 2026 |
| NCT07222748 | Ropivacaine (TLC590) | Phase 3 | Postoperative Pain | Other | Jun 2026 |
| NCT06574269 | Ropivacaine (TLC590) | Phase 2 | Postsurgical Pain Management | Other | Jul 2026 |
| NCT05953766 | Ropivacaine (TLC590) | Phase 2 | Post-operative Pain | Other | Jul 2026 |
| NCT06511765 | Ropivacaine (TLC590) | Phase 3 | Lumbago | Other | Sep 2026 |
| NCT03737604 | Ropivacaine (TLC590) | Phase 4 | Transplant;Failure,Kidney | Genitourinary | Sep 2026 |
| NCT03230565 | Ropivacaine (TLC590) | Phase 4 | Surgical Procedure, Unspecified | Other | Dec 2026 |
| NCT04130464 | Ropivacaine (TLC590) | Phase 4 | Hysterectomy | Other | Dec 2026 |
| NCT04130464 | Ropivacaine (TLC590) | Phase 4 | Hysterectomy | Other | Dec 2026 |
| NCT06189781 | Ropivacaine (TLC590) | Phase 4 | Cerebral Palsy | Neurology | Dec 2026 |
| NCT06189781 | Ropivacaine (TLC590) | Phase 4 | Cerebral Palsy | Neurology | Dec 2026 |
| NCT07349810 | Ropivacaine (TLC590) | Phase 4 | Post Operative Pain | Other | Dec 2026 |
| NCT07006168 | Ropivacaine (TLC590) | Phase 4 | Patella Fracture | Other | Dec 2026 |
| NCT03796572 | Ropivacaine (TLC590) | Phase 4 | Fractures, Closed | Other | Jan 2027 |
| NCT06875427 | Ropivacaine (TLC590) | Phase 3 | Anterior Cruciate Ligament | Other | Jan 2027 |
| NCT06008795 | Ropivacaine (TLC590) | Phase 2 | Subarachnoid Hemorrhage, Aneurysmal | Cardiovascular | Jan 2027 |
| NCT07023094 | Ropivacaine (TLC590) | Phase 4 | Hip Disease | Other | Jan 2027 |
| NCT07023094 | Ropivacaine (TLC590) | Phase 4 | Hip Disease | Other | Jan 2027 |
| NCT07023094 | Ropivacaine (TLC590) | Phase 4 | Hip Disease | Other | Jan 2027 |
| NCT07023094 | Ropivacaine (TLC590) | Phase 4 | Hip Disease | Other | Jan 2027 |
| NCT06406010 | Ropivacaine (TLC590) | Phase 4 | Anesthesia, Local | Other | Feb 2027 |
| NCT05642026 | Ropivacaine (TLC590) | Phase 4 | Rib Fractures | Other | Feb 2027 |
| NCT05889741 | Ropivacaine (TLC590) | Phase 2 | Stress Disorders, Post-Traumatic | Psychiatry | Mar 2027 |
| NCT03632044 | Ropivacaine (TLC590) | Phase 4 | Mouth Abnormalities | Other | May 2027 |
| NCT04011150 | Ropivacaine (TLC590) | Phase 3 | Labor Pain | Other | Aug 2027 |
| NCT07116343 | Ropivacaine (TLC590) | Phase 4 | Cardiac Surgery | Cardiovascular | Sep 2027 |
| NCT07180979 | Ropivacaine (TLC590) | Phase 4 | Hip Osteoarthritis | Immunology | Sep 2027 |
| NCT07180979 | Ropivacaine (TLC590) | Phase 4 | Hip Osteoarthritis | Immunology | Sep 2027 |
| NCT07092566 | Ropivacaine (TLC590) | Phase 3 | Renal Carcinoma | Oncology | Oct 2027 |
| NCT07666178 | Ropivacaine (TLC590) | Phase 3 | Erector Spinae Plane Block | Other | Dec 2027 |
| NCT02278601 | Ropivacaine (TLC590) | Phase 3 | Breakthrough Pain | Other | Dec 2027 |
| NCT07414706 | Ropivacaine (TLC590) | Phase 3 | Intravenous Lidocaine | Other | Jun 2028 |
| NCT04065009 | Ropivacaine (TLC590) | Phase 3 | Advanced Ovarian Cancer | Oncology | Sep 2028 |
| NCT05969457 | Ropivacaine (TLC590) | Phase 3 | Hysterotomy; Affecting Fetus | Other | Sep 2029 |
Shenzhen Ausa Pharmed LXO Ireland Xenon Pharmaceuticals Newron Pharmaceuticals Lupin
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.